{"meshTags":["Neoplasm Staging","Aged","Humans","Melanoma","Antineoplastic Agents","Phenylurea Compounds","Proto-Oncogene Proteins c-kit","Anus Neoplasms","Treatment Outcome","Male","Niacinamide","Pyridines","Benzenesulfonates","Dacarbazine"],"meshMinor":["Neoplasm Staging","Aged","Humans","Melanoma","Antineoplastic Agents","Phenylurea Compounds","Proto-Oncogene Proteins c-kit","Anus Neoplasms","Treatment Outcome","Male","Niacinamide","Pyridines","Benzenesulfonates","Dacarbazine"],"genes":["KIT Val560Asp","KIT","vascular endothelial growth factor platelet-derived growth factor receptor alpha and beta","MLH1","MSH2","MSH6"],"organisms":["9606","9606"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"A 79-year-old man presented to his primary care physician with a 2-month history of pruritus ani and a pigmented nodular lesion was discovered in the posterior rectum. The patient had no other symptoms, or any family history of malignancy.\nPhysical examination; excisional biopsy; CT scan of the chest, abdomen and pelvis; lung biopsy; blood tests; tumor immunohistochemistry for KIT, vascular endothelial growth factor platelet-derived growth factor receptor alpha and beta, and mismatch-repair proteins MLH1, MSH2, and MSH6; and KIT and BRAF tumor genotyping.\nStage IV M1b metastatic anal mucosal melanoma.\nWide local excision with mucosal advancement of the rectal wall, external-beam radiation, and sorafenib-temozolomide therapy.","title":"Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.","pubmedId":"18936790"}